学術論文　2013

  1. Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, et al. IL-28B (IFN-lambda3) and IFN-alpha synergistically inhibit HCV replication. J Viral Hepat 2013;20:281-289.
  2. Muhi A, Ichikawa T, Motosugi U, Sano K, Fatima Z, Matsuda M, Fujii H, et al. Diffusion-weighted imaging of hepatocellular carcinoma for predicting early recurrence and survival after hepatectomy. Hepatol Int 2013;7:662-668.
  3. Motosugi U, Ichikawa T, Koshiishi T, Sano K, Morisaka H, Ichikawa S, Enomoto N, et al. Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study. Eur Radiol 2013;23:156-162.
  4.  Motosugi U, Ichikawa T, Araki T, Matsuda M, Fujii H, Enomoto N. Bayesian prediction for liver fibrosis staging: combined use of elastography and serum fibrosis markers. Hepatology 2013;58:450-451.
  5. Morisaka H, Motosugi U, Ichikawa T, Sano K, Ichikawa S, Araki T, Enomoto N. MR-based measurements of portal vein flow and liver stiffness for predicting gastroesophageal varices. Magn Reson Med Sci 2013;12:77-86.
  6. Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, et al. Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. J Virol 2013;87:12541-12551.
  7. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, et al. Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol 2013;85:449-458.
  8. Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, et al. Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. Hepatol Res 2013;43:865-875.
  9. Kadokura M, Iwasa S, Honma Y, Kato K, Hamaguchi T, Yamada Y, Enomoto N, et al. Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer. Anticancer Res 2013;33:4547-4552.
  10. Chen N, Motosugi U, Sano K, Ichikawa T, Nakano M, Morisaka H, Ichikawa S, et al. Early hepatocellular carcinomas showing isointensity or hyperintensity in gadoxetic acid-enhanced, hepatocyte-phase magnetic resonance images. J Comput Assist Tomogr 2013;37:466-469.
  11. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253-1262.